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Atherosclerosis, the leading cause of death in the
Western world, is driven by chronic inflammation
within the artery wall. Elements of the complement
cascade are implicated in the pathogenesis, because
complement proteins and their activation products
are found in the atherosclerotic plaque. We examined
the role of CD55, a membrane inhibitor of the com-
plement component 3 (C3) convertase, which con-
verts C3 into C3a and C3b, in atherosclerosis. CD55-
deficient (CD55/) mice were crossed onto the
atherosclerosis-prone apolipoprotein E (apoE)-defi-
cient (apoE/) background. High fat–fed male
apoE//CD55/mice were strongly protected from
developing atherosclerosis compared with apoE/
controls. Lipid profiling showed significantly lower
levels of triglycerides, nonesterified fatty acids, and
cholesterol in apoE//CD55/ mice than that in
controls after high-fat feeding, whereas body fat
in apoE//CD55/ mice content was increased.
Plasma levels of C3 fell, whereas concentrations of
C3adesArg (alias acylation stimulating protein;
ASP), produced by serum carboxypeptidase N–me-
diated desargination of C3a, increased in nonfasted
high fat–fed apoE//CD55/ mice, indicating
complement activation. Thus, complement dysregu-
lation in the absence of CD55 provoked increased
C3adesArg production that, in turn, caused altered
lipid handling, resulting in atheroprotection and
increased adiposity. Interventions that target com-
plement activation in adipose tissue should be ex-plored as lipid-decreasing strategies. (Am J Pathol
2011, 179:1601–1607; DOI: 10.1016/j.ajpath.2011.06.015)
Atherosclerosis, long considered a passive process of
accumulation of lipid in blood vessel walls accompanied
by smooth muscle proliferation and culminating in loss of
endothelial integrity, is now recognized as an active pro-
cess with immune cells and mediators accumulating in
forming plaques from the earliest stages, and inflamma-
tion central to disease progression.1,2 Both innate immu-
nity and adaptive immunity play roles, with mediators of
both arms of the immune system present in the plaque.3
Among the innate immune components, complement (C)
and its activation products are abundant and suggested
to play critical roles in atherogenesis, both directly
through local cell damage and indirectly by attracting
and activating immune cells.4–9 C comprises three acti-
vation pathways, alternative, classical, and lectin, and
activation of each has been shown in atherosclero-
sis.10–12 Effector molecules generated during C activa-
tion include anaphylactic and chemotactic fragments
(C3a, C5a), opsonic fragments (C4b, C3b), and the cy-
totoxic membrane attack complex (MAC). C3a and C5a
may promote infiltration of inflammatory cells into the
plaque13,14; this activity is regulated by carboxypepti-
dase N, which clips the carboxy-terminal arginine. Al-
though C3adesArg is inactive as an inflammatory medi-
ator, a growing body of literature reports that it has potent
adipogenic activity, promoting lipid uptake, triglyceride
synthesis, and storage in adipocytes.15,16 C3-deficient
mice, which cannot generate C3adesArg, have delayed
postprandial triglyceride clearance, together with higher
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cantly reduced adiposity than do wild types.17,18
Animal models have contributed to establishing the rele-
vance of C to atherosclerosis. Almost 40 years ago, studies
in fat-fed C6-deficient rabbits showed that absence of C6,
an essential component of the MAC, markedly inhibited
plaque formation,19 findings replicated and extended more
recently.20 Atherosclerosis-prone mouse strains back-
crossed onto C-deficient strains have been used to further
explore roles of C. Fat-fed apolipoprotein E (apoE)-deficient
(apoE/) mice lacking C6 showed significantly attenuated
disease, replicating findings in rabbits, whereas absence of
CD59a, the principle murine regulator of MAC assembly,
exacerbated disease.21–23 In contrast, deficiency of C5,
removing the capacity to form C5a and MAC, had no effect
on atherosclerosis progression in apoE/mice,24 whereas
deficiency of C3, but not factor B, exacerbated plaque
formation and caused hyperlipidemia on apoE//ldlr/ or
ldlr/ backgrounds.25,26
CD55 (decay accelerating factor) is a 70-kDa mem-
brane-bound C regulator that accelerates decay of the
C3 convertase. To test the effect of CD55 deficiency on
progression of atherosclerosis, CD55/ mice were
back-crossed onto the apoE/ background and fed an
atherogenic diet. Informed by our findings with CD59a
deficiency, we anticipated that CD55 deficiency would
exacerbate disease. Instead, deficiency of CD55 was
highly protective for atherosclerosis; plaques were
smaller and remained structurally simple. We here show
that altered lipid handling resulting from C dysregulation
is responsible for reduced atherogenesis in CD55/
mice. The demonstration that C activation products mark-
edly affect lipid handling and plaque formation will influ-
ence future strategies for treatment of atherosclerosis.
Materials and Methods
Reagents and Animals
All chemicals were purchased from Sigma-Aldrich (Poole,
UK) or Fisher Scientific (Loughborough, UK). Fatty acid and
lipid standards were from Nu-Chek-Pre Inc. (Elysian, MN)
and Sigma-Aldrich, respectively. Silica gel G plates were
from Merck KGaA (Darmstadt, Germany).
CD55 knockout (CD55/) mice were provided by Prof
Wenchao Song (University of Philadelphia, Philadelphia,
PA) and back-crossed onto C57BL/6 for nine genera-
tions. ApoE/ mice were originally provided by J.
Breslow (Rockefeller University, New York, NY). The
strain background of these original mice was 71%
C57BL/6 and 29% 129. The apoE/ mice were crossed
with CD55/ mice to generate apoE//CD55/ dou-
ble knockouts along with apoE/ single knockouts;
these sex-, strain-, and age-matched littermates provided
the appropriate controls. Mice were genotyped by poly-
merase chain reaction with the use of genomic DNA
extracted from tail tips.
Male mice aged 8 weeks were fed a high-fat diet,
containing 21% (wt/wt) pork lard and supplemented with
0.15% (wt/wt) cholesterol (Special Diet Services, Witham,UK), for 12 weeks. Animals were housed in a specific
pathogen-free environment. Some mice were deprived of
food for 16 hours overnight to obtain baseline levels of
various parameters. All studies and protocols were ap-
proved by the institutional ethics review committee and
the United Kingdom Home Office and conformed to the
Guide for the Care and Use of Laboratory Animals (NIH
Publication No. 85–23, revised 1996).
Histology and Immunohistochemistry
Mice were anesthetized by intraperitoneal injection of so-
dium pentobarbitone and weighed before exsanguination
by arterial perfusion via the abdominal aorta with PBS at a
constant pressure of 100 mmHg, with outflow through the
incised jugular veins. Brachiocephalic arteries were re-
moved with a piece of the aortic arch and the stump of the
right subclavian artery still attached to aid orientation during
processing, immediately embedded in optimum cutting
temperature compound (RA Lamb Ltd, Eastbourne, UK),
and snap-frozen in liquid N2.
Serial transverse 7-m sections were cut along the
brachiocephalic artery, starting from the proximal end.
Sections were stained with Miller’s Elastic/Van Gieson
(Sigma-Aldrich). Macrophages and smooth muscle cells
were identified with anti-murine macrophage mAb (di-
luted 1:100; F4/80; Serotec, Oxford, UK) and anti–-
smooth muscle actin mAb (diluted 1:100; clone 1-A4;
Sigma-Aldrich), respectively. Sections were fixed in ice-
cold acetone and blocked with either avidin/biotin block-
ing kit (Vector Laboratories, Peterborough, UK) followed
by 10% goat serum or Mouse-on-Mouse kit (Vector Lab-
oratories). Blocked sections were incubated with appro-
priate biotinylated secondary antibodies: goat anti-rat Ig
(Vector Laboratories; 3.5 g/mL in 10% mouse serum) or
anti-mouse Ig diluted as directed (Mouse-on-Mouse kit).
Staining was developed with Fluorescein-Avidin D (di-
luted 1:200 in 2% bovine serum albumin in PBS; Vector
Laboratories), and cell nuclei were counterstained with
DAPI (Sigma-Aldrich).
Immunostaining for C activation used either rat anti-
mouse C3b/iC3b mAb clone 2/11 (5 g/mL; Hycult Bio-
tech) or affinity-purified rabbit anti-rat/mouse C9 gener-
ated in house, proven reactive with MAC in mouse tissues
(2 g/mL).23 For C3 and C9 staining, sections were fixed
in acetone at 4°C, blocked in 2% bovine serum albumin
in PBS, and, after staining with primary antibody, devel-
oped with either Alexa Fluor 488–labeled goat anti-rat
(20 g/mL; Invitrogen, Carlsbad, CA) or Alexa Fluor 594–
labeled goat anti-rabbit IgG (20 g/mL; Molecular
Probes, Eugene, OR) respectively. Nuclei were counter-
stained with DAPI.
Negative controls included replacement of primary an-
tibody with IgG isotype control. Staining was expressed
as the percentage of lesion area staining positive, as-
sessed by computerized image analysis (Image ProPlus
4.0; Media Cybernetics, Carlsbad, CA).
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Five sections were taken per mouse at the same relative
positions along the brachiocephalic artery and were as-
sessed for the presence of plaque with the use of an
established method.25 Plaque area was calculated with
image analysis as above.
Measuring Serum Triglycerides, Cholesterol,
and NEFAs
Mice were sacrificed between 9 AM and 11 AM, blood
(1 mL) was collected into tubes with or without EDTA, and
serum or plasma was separated by centrifugation. Tri-
glyceride and cholesterol levels were measured at the
Clinical Biochemistry Laboratories, University Hospital
Cardiff, on an Aeroset automated analyzer (Abbott Diag-
nostics, Berkshire, UK). For NEFAs, lipids were extracted
and separated by one-dimensional thin-layer chromatog-
raphy on 10  10-cm silica gel G plates, double devel-
oped with toluene/hexane/formic acid (140:60:1, v/v/v) for
the entire plate, followed by hexane/diethyl ether/formic
acid (60:40:1, v/v/v) to half height. Plates were sprayed
with 0.05% (wt/v) 8-anilino-4-naphthosulphonic acid in
methanol and viewed under UV light to show lipids. Free
fatty acids were scraped from the plate and were identi-
fied and quantified by gas chromatography.
Measuring C3adesArg
C3adesArg was measured in a sandwich ELISA with the
use of a pair of anti-mouse C3a mAbs, one unlabeled as
capture (0.2 g/mL), the other biotinylated as detection (0.5
g/mL), and recombinant mouse C3a (100 to 0.78 ng/mL)
as standards (all from BD Pharmingen, San Diego, CA).
Appropriately diluted plasma samples were included. The
assay was developed with streptavidin-peroxidase (1:5000;
Jackson ImmunoResearch, West Grove, PA).
Measuring Mouse C3
Serum C3 levels were measured by ELISA essentially as pre-
viously described,27 except that rat anti-mouse C3 (2 g/mL;
clone 11H9; Hycult Biotech) was used as the capture anti-
body. A standard curve of known concentrations, starting from
0.5g/mL,wasproducedwith the use of purifiedmouseC3 (a
kind gift from Dr Claire Harris; Cardiff University).
Body Fat Measurement
Percentage of body fat was measured by dual-energy
X-ray absorptiometry scanning of whole animals with the
use of a PIXImus scanner (Lunar Corp, Madison, WI) with
small animal software.
Statistical Analysis
Data are expressed as mean SEM, and significance was
tested by two-tailed unpaired Student’s t-test (GraphPad
Prism software, version 3.0; GraphPad Software Inc., San
Diego, CA), with significance assumed at P  0.05.Results
Deficiency of CD55 Protects from
Atherosclerosis in apoE/ Mice
Matched apoE/ and apoE//CD55/ mice were sacri-
ficed at 20 weeks of age after 12 weeks on a high-fat diet,
and the extent of atherosclerosis was assessed in the bra-
chiocephalic arteries, a known site of predilection for
plaque development.28 Plaque cross-sectional area, as-
sessed at multiple sites along the vessel, was reduced
threefold in apoE//CD55/ mice compared with
apoE/ controls (54.7  11.2  103 m2 versus 155.2 
16.8  103 m2; P  0.001; Figure 1, A–C). Plaque stage
and complexity were further explored by measuring smooth
muscle cell content and macrophage infiltration; smooth
muscle cells as a proportion of total cell number in apoE//
CD55/ plaques were significantly lower than in apoE/
plaques (9.3%  2.0% versus 18.0%  2.8%; P  0.05;
Figure 1, D–F). Plaque macrophage content was simi-
lar in the groups (19.4%  6.5% versus 18.8%  4.2%;
Figure 1, G–I).
To address whether CD55 deficiency influenced local C
activation, plaques were stained for C3 fragments and
MAC. C3 fragment deposition was assessed with mAb
3/26, a neoepitope-specific mAb that specifically detects
C3b, iC3b, and C3c in tissues, whereas MAC was detected
with affinity-purified anti-rat/mouse C9. Percentages of
plaque area stained for C3b/iC3b/C3c and MAC were two-
fold reduced in plaques from apoE//CD55/mice com-
pared with apoE/ controls (C3b/iC3b/C3c: 28.0% 8.1%
versus 57.3%  7.7%; P  0.05; Figure 1, J–L; MAC:
17.9%  3.5% versus 30.5%  4.0%; P  0.05; Fig-
ure 1, M–O).
CD55 Deficiency Is Associated with Reduced
Serum Triglyceride and Cholesterol Levels
To test whether the absence of CD55 affected lipid han-
dling, lipid levels were measured in apoE//CD55/
mice and in apoE/ controls at 8 weeks old on normal
diet and at 20 weeks old after 12 weeks on a high-fat diet.
At 8 weeks, triglyceride levels were markedly reduced in
the apoE//CD55/ mice than in the apoE/ controls
(2.1  0.1 mmol/L versus 5.1  0.6 mmol/L; P  0.01;
Figure 2A); cholesterol levels were not significantly differ-
ent between these groups (16.1  1.4 mmol/L versus
18.2  0.8 mmol/L; Figure 2B). After 12 weeks of fat
feeding, triglyceride levels were little changed, as ex-
pected in the apoE/ model,29 and remained signifi-
cantly lower in the apoE//CD55/ mice compared
with the apoE/ controls (1.7 0.2 mmol/L versus 3.6
0.5 mmol/L; P  0.01; Figure 2A). Cholesterol levels were
increased after 12 weeks of fat feeding in both groups but
were significantly lower in the apoE//CD55/ mice
than in the apoE/ controls (29.0  1.8 mmol/L versus
38.3 2.5 mmol/L; P 0.01; Figure 2B). Plasma levels of
NEFAs were measured in mice before and after being fed
the high-fat diet. Significant increases in NEFA concen-
trations were seen in both groups after 12 weeks of a
apoE -/-/C
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AJP October 2011, Vol. 179, No. 4high-fat diet (apoE//CD55/: 0.153  0.016 mg/mL
versus 0.333 0.041 mg/mL before and after the high-fat
diet, respectively; P  0.001; apoE/: 0.121  0.006
mg/mL versus 0.505 0.046 before and after the high-fat
diet, respectively; P  0.001; Figure 2C). Although no
significant differences were observed in NEFA levels be-
tween apoE/CD55/ and apoE/ mice before fat
feeding, levels were significantly lower in apoE//
CD55/mice than in apoE/ controls after 12 weeks on
a high-fat diet (0.333  0.041 mg/mL versus 0.505 
0.046 mg/mL; apoE//CD55/ and apoE/, respec-
tively; P  0.01; Figure 2C).
CD55 Deficiency Is Associated with Increased
C3 Turnover and Plasma C3adesArg Levels
C3adesArg, also known as ASP, is a stable product of C3
activation and a potent adipokine that stimulates uptake
of triglycerides and NEFAs, enhances triglyceride syn-
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B Cthesis and storage, and inhibits triglyceride lipolysis inadipose tissue.30–32 Circulating nonfasting C3 and its
activation product C3adesArg (Figure 2, D and E, re-
spectively) were measured before and after the high-fat
feeding in apoE//CD55/ and apoE/ mice. C3 lev-
els were significantly reduced in both apoE//CD55/
and apoE/ mice after 12 weeks of high-fat feeding
compared with before the high-fat feeding values (apoE//
CD55/: 0.42  0.03 mg/mL versus 0.3  0.04 mg/mL;
P  0.01, respectively; apoE/ 0.48  0.05 mg/mL
versus 0.22  0.05 mg/mL; P  0.05, respectively). C3
levels were not significantly different between apoE//
CD55/ and apoE/ mice at either time point (Figure
2D). Plasma C3adesArg levels were markedly lower after
being deprived of food overnight compared with not be-
ing deprived of food regardless of age, diet, and geno-
type of the mice (compare Figure 2, E with F). Fasting
C3a levels were similar in all groups of mice (Figure 2F);
in contrast, nonfasting C3adesArg levels were signifi-
cantly higher in apoE//CD55/ mice than in apoE/
55-/- apoE -/-
**
55-/- apoE-/-
*
D55-/- apoE -/-
**
55-/- apoE -/-
D55 -/- apoE -/-
**
Figure 1. Assessment of atherosclerosis in bra-
chiocephalic arteries of apoE//CD55/ and
apoE/ control mice after 12 weeks of high-fat
feeding. Histologic appearance of representa-
tive sections of brachiocephalic arteries from a
single experiment that compared apoE//
CD55/ mice (A, D, G, J, and M) with
apoE/ control mice (B, E, H, K, and N); both
groups had been fed a high-fat diet for 12
weeks. Sections were stained with Miller’s/Elas-
tic Van Gieson (A and B; n  13 and 12, respec-
tively); immunostained for -smooth muscle ac-
tin (smooth muscle cells; D and E; n  7 and 7,
respectively); F/480 (macrophages; G and H;
n  8 and 6, respectively); C3 fragments (J and
K; n  7 and 6, respectively), or MAC deposi-
tion (M and N; n  7 and 7, respectively). Scale
bars: 200 m (A, B, D, E, G, H, J, K, M, and N).
C, F, I, L, and O: Composite data from each
group compiled from digital analyses of individ-
ual sections as described in Materials and Meth-
ods. C: Average plaque size for the two groups
as determined from five individual sections
taken from each mouse. F, I, L, and O: Mean
percentage of plaque area staining for smooth
muscle cells, macrophages, C3b/iC3b/C3c, and
MAC, respectively. Mean values  SEM are rep-
resented. *P  0.0001, **P  0.05.apoE -/-/CD
apoE-/-/CD
apoE-/-/CD
apoE -/-/Cmice but only on the high-fat diet (Figure 2E; 1.58  0.14
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show that high-fat feeding in apoE//CD55/ mice is
associated with increased C3 turnover and higher circu-
lating levels of C3adesArg compared with apoE/ con-
trols.
ApoE//CD55/ Mice Have Increased
Adipose Tissue Content
To test whether the observed changes in circulating lipid
levels and C3 activation in high fat–fed apoE//CD55/
mice affected fat storage, body weight and composition
were compared between the groups. The high-fat diet
caused significant increases in body weight for both
groups, without any significant differences between
Figure 2. Assessment of lipid profile, C3 and C3adesArg levels in apoE//
CD55/ and apoE/ mice. Serum levels of triglycerides, cholesterol, NEFAs,
C3, and plasma C3adesArg were assayed in apoE//CD55/ and apoE/
mice at 8 weeks of age (before high-fat diet; Pre-HFD) and at 20 weeks after 12
weeks of high-fat diet (Post-HFD). A: Serum triglyceride levels (Pre-HFD, n 4
and 6, respectively; Post-HFD, n 12 and 15, respectively).B: Serum cholesterol
levels (Pre-HFD, n  4 and 6, respectively; Post-HFD, n  12 and 15, respec-
tively). C: Serum NEFA levels (Pre-HFD, n  6 and 6, respectively; Post-HFD,
n  12 and 14, respectively). D: Total serum C3 levels (Pre-HFD, n  6 and 6,
respectively; Post-HFD, n  6 and 4, respectively). E: Plasma nonfasting
C3adesArg levels (Pre-HFD, n 6 and 8, respectively; Post-HFD, n 11 and 12,
respectively). F: Plasma fasting C3adesArg levels (Pre-HFD, n  8 and 7, re-
spectively; Post-HFD, n  11 and 11, respectively). Mean values  SEM are
represented. *P  0.05, **P  0.01, and ***P  0.0001.apoE//CD55/ mice and apoE/ controls (apoE//CD55/: 27.32  0.6 g versus 38.16  2.12 g; P 
0.0001; apoE/: 30.64  0.39 g versus 41.38  1.17 g;
P  0.0001).
Both adipose mass and percentage of body fat were
measured with dual-energy X-ray absorptiometry (Figure
3, A and B, respectively). After 12 weeks of high-fat
feeding CD55 deficiency was associated with increased
adipose tissue mass and percentage of body fat, signif-
icant in the latter case, in apoE//CD55/ mice com-
pared with apoE/ controls (Figure 3B; before high-fat
diet: 17.43%  0.64%; 17.8%  1.11% apoE//
CD55/ versus apoE/, respectively; after high-fat
diet: 28.63%  4.18%; 19.54%  1.77% apoE//
CD55/ versus apoE/, respectively; P  0.05).
Discussion
We here demonstrate that CD55 deficiency in fat-fed
male apoE/ mice markedly attenuated the progression
of atherosclerosis. Plaques were infrequent, small, and
structurally simple, having fewer smooth muscle cells
and less neo-intimal thickening in comparison with their
apoE/ controls, which displayed large, advanced
plaques at the same time point.
We previously showed that MAC deposition correlates
with plaque stage, probably reflecting the increased
amount of C-activating cell debris in advanced lesions.23
The data show that, despite global absence of the C
regulator CD55, C activation is reduced in the early,
simple plaques formed in apoE//CD55/ mice. These
results are surprising in that the absence of an important
C regulator would be predicted to exacerbate injury in a
disease characterized by C activation; indeed, defi-
ciency of CD59a markedly exacerbated MAC formation
and disease in atherosclerosis-prone mice.21–23 Two re-
cent studies tested effects of CD55 deficiency in athero-
sclerosis models. Leung et al27 showed exacerbated dis-
ease and increased plaque size in female CD55//
ldlr/ mice compared with the ldlr/ controls. This
contradictory result is probably because of the different
atherosclerosis-prone background; deficiency of ldlr
causes a more severe metabolic derangement and de-
ranged lipid profiles compared with apoE deficiency.29
Figure 3. Measurement of adipose tissue mass and percentage of body fat in
apoE//CD55c/ and apoE/ mice. Adipose tissue mass (A) and per-
centage of body fat (B) were measured by dual-energy X-ray absorptiometry
in apoE//CD55/ and apoE/ mice at 8 weeks of age (before high-fat
diet; Pre-HFD; n  6 and 8, respectively) and at 20 weeks of age after 12
weeks of high-fat diet (Post-HFD, n  6 and 9, respectively). Mean values 
SEM are represented. *P  0.05.
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mice on a high-fat diet for 8 or 16 weeks. Plaque area,
measured at end point in the aortic arch, was not signif-
icantly different in apoE//CD55/ and apoE/
groups; however, when separated according to sex,
there was a clear trend, not remarked on by the investi-
gators, toward smaller plaques in male apoE//
CD55/ mice after 16 weeks of the high-fat diet. Group
sizes after dividing by sex were small, and the differ-
ences observed were not significant. These published
findings support our observation, probably made signif-
icant in our study by the use of larger group sizes and
male mice. Indeed, many inbred mouse strains, including
C57BL/6, have a constitutively more active hemolytic C
system because of differences in activation and lytic
pathways.34–36 Remarkably, apoE//CD55/mice had
a markedly altered lipid profile, dominated by low circu-
lating triglyceride, NEFA, and cholesterol levels; in-
creased triglyceride uptake into adipose tissue and fat
synthesis resulted in increased adiposity. Two hypothe-
ses were considered to explain the above findings: first,
that CD55 played a direct role in lipid metabolism inde-
pendent of its role in regulating C, and, second, that the
absence of CD55 caused increased C3 turnover that in
turn influenced lipid handling. Others have shown that C3
deficiency on atherosclerosis-prone backgrounds exac-
erbated hyperlipidemia and atherogenesis.25,26 This ob-
servation favored a role for C3, provoking us to ask
whether C3 turnover was altered in CD55/ mice and
contributed to the observed lipid profile and atheropro-
tection. C3 levels were significantly reduced in both
apoE/ and apoE/CD55/ mice when fed a high-fat
diet, suggesting that a high-fat diet provoked C3 con-
sumption. Remarkably, although C3adesArg levels were
low in all mice after being deprived of food overnight,
levels in mice not deprived of food were markedly higher
and were significantly increased in high fat–fed apoE//
CD55/ mice compared with apoE/ controls. These
data imply that the observed changes in lipid profile were
caused by diminished capacity, in the absence of CD55,
to regulate the C3 convertase, resulting in dysregulation
of the ASP pathway and increased production of
C3adesArg/ASP in response to circulating chylomicrons
or very low density lipoprotein particles.37–39 Although
hypercholesterolemia has been the focus of most atten-
tion in atherosclerosis, elevated triglyceride and NEFA
levels are recognized as independent risk factors for
atherogenesis in humans and models.40,41 Indeed, the
antiatherogenic effects of lipoic acid in the apoE/
model were shown to be due to its triglyceride-lowering
properties.42 It is therefore probable that the observed
antiatherogenic effect of CD55 deficiency is due to the
combined effects of lower plasma levels of triglycerides,
cholesterol, and NEFAs.
These findings support in vitro and in vivo studies that
implicate chylomicrons and/or very low density lipopro-
tein as the primary physiological trigger for C3adesArg/
ASP production from adipose tissue.43,44 In vitro, expo-
sure of adipose tissue to purified chylomicrons switched
on the ASP pathway, markedly increasing synthesis of
precursor C3 and generation of C3adesArg, whereas, invivo, chylomicronemia acutely increased plasma C3 and
C3adesArg/ASP levels.43,44 The amount of C3adesArg/
ASP generated will depend on the local activity and reg-
ulation of C3 convertase, in turn depending on the pres-
ence and abundance of C regulators. CD55 is expressed
on adipose cells45,46 and will therefore contribute to local
regulation of the convertase; in its absence, the conver-
tase will persist and generate more C3adesArg/ASP.
Because C3adesArg/ASP is such a critical factor in
maintaining lipid homeostasis, a persistent increase in
local and circulating levels could be predicted to affect
lipid profiles in precisely the manner observed in the
apoE//CD55/mice of the current study by provoking
increased uptake of triglycerides and NEFAs into adi-
pose tissue, resulting in reduced plasma levels. We
chose to use male mice in this study because of proven
differences in C activity and have suggested that failure
to detect this effect of CD55 in previous studies was due
to inclusion of female mice. A further potential confounder
is the effect of sex hormones on the ASP pathway. Pro-
gesterone down-regulates the expression of C5L2, the
receptor for C3adesArg, in 3T3 adipocytes, potentially
rendering female mice less responsive to C3adesArg
and blunting the atheroprotective effect of CD55 defi-
ciency seen in male apoE//CD55/ mice.47
The chain of events shown here explains both athero-
protection and increased adiposity in the mice and also
provides an explanation for the enigmatic observation
that C3-deficient mice, lacking the capacity to generate
C3adesArg, show accelerated disease in models of ath-
erosclerosis.25,26 The data show that C3adesArg itself, or
agents mimicking its lipid-modulating effects, might be of
benefit in the treatment of atherosclerosis and related
diseases.
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